226 related articles for article (PubMed ID: 35508970)
1. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.
Krasenbaum LJ; Pedarla VL; Thompson SF; Tangirala K; Cohen JM; Driessen MT
J Headache Pain; 2022 May; 23(1):54. PubMed ID: 35508970
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U
J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
[TBL] [Abstract][Full Text] [Related]
4. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
5. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.
Driessen MT; Cohen JM; Patterson-Lomba O; Thompson SF; Seminerio M; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 Apr; 23(1):47. PubMed ID: 35410121
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
8. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
9. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
Buse DC; Krasenbaum LJ; Seminerio MJ; Packnett ER; Carr K; Ortega M; Driessen MT
Pain Ther; 2024 Jun; 13(3):511-532. PubMed ID: 38472655
[TBL] [Abstract][Full Text] [Related]
10. Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Pazdera L; Cohen JM; Ning X; Campos VR; Yang R; Pozo-Rosich P
Cephalalgia; 2021 Sep; 41(10):1075-1088. PubMed ID: 33990144
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
12. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
[TBL] [Abstract][Full Text] [Related]
14. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
15. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
17. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V; Russo A; Silvestro M; Tessitore A; De Icco R; Vaghi G; Sances G; Tassorelli C; Baraldi C; Castro FL; Guerzoni S; Prudenzano MP; Fallacara A; Gentile M; Ornello R; Onofri A; Burgalassi A; Chiarugi A; De Cesaris F; Granato A; Casalena A; De Tommaso M; Mampreso E; Merlo P; Coppola G; Battistini S; Rebecchi V; Rainero I; Sepe FN; Dalla Volta G; Sacco S; Geppetti P; Iannone LF;
CNS Drugs; 2023 Dec; 37(12):1069-1080. PubMed ID: 37999868
[TBL] [Abstract][Full Text] [Related]
19. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]